Swedish pharmaceutical company Newbury Pharmaceuticals AB (STO:NEWBRY) said on Wednesday that it has received marketing authorisation for Bosutinib Newbury in Norway.
This marks the first step in a Scandinavian registration process, with approvals expected in Sweden and Denmark soon.
Bosutinib Newbury is a generic version of Bosulif, indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML).
This approval provides access to an important treatment option for patients in the Scandinavian market, estimated to be worth EUR5.5m annually.
Esperion settles with Dr. Reddy's Laboratories on NEXLETOL and NEXLIZET generics
Mint Pharmaceuticals forms distribution partnership with Bayer Canada
Padagis collaborates with The Naloxone Project to address opioid overdose crisis
Biocon's first US manufacturing facility inaugurated in Cranbury, New Jersey
Amneal's risperidone extended-release injectable suspension approved by US FDA
First FDA acceptance to waive clinical efficacy studies for monoclonal antibody biosimilars
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Viatris' generic iron sucrose injection gains US FDA approval